Elogium, a biotechnology company, has developed EloSafe+, a probiotic feed additive designed to reduce Campylobacter colonization in poultry without antibiotics. Campylobacter is a major foodborne pathogen affecting over 9% of the global population annually, with poultry as the primary carrier.
EloSafe+ uses a strain of Bacillus subtilis PS-216, originally isolated from riverbank soil in Slovenia. Research shows it significantly reduces Campylobacter, including antibiotic-resistant strains, as well as Salmonella and Listeria in poultry. In-vivo studies indicate a 1.4-log reduction in Campylobacter levels in broiler chickens and up to 2.6% improvement in feed conversion rates.
As antibiotic restrictions tighten, poultry producers are seeking alternatives. EloSafe+ provides a scientifically validated, antibiotic-free solution that improves food safety and farm sustainability. Elogium is also exploring applications for swine, cattle, and aquaculture.
The company, recognised in European biotech incubators, is advancing through regulatory approval with the European Food Safety Authority (EFSA). Large-scale trials are underway, and Elogium anticipates full market approval by 2027. Strategic partnerships with animal health firms aim to accelerate commercialization, with Elogium targeting a 10% market share in Europe within five years.
With industry backing and regulatory momentum, EloSafe+ positions Elogium at the forefront of next-generation probiotic solutions for animal agriculture.